Verily Life Sciences
-
BioPharma, Patient Engagement, Pharma, SYN
Verily joins with Janssen, adding Covid-19 to Project Baseline study
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
-
Culture Biosciences raises $15M in Series A funding round
The company plans to triple its biomanufacturing R&D capacity beyond what it is currently and also develop new software programs. The company has more than 30 customers, ranging from startups to large firms.
-
Streamline the Process for Consent Collection and Management
Join us on April 16th and hear executives from DocuSign and Velatura discuss how their partnership modernizes and facilitates the efficient and secure completion of the patient consent form.
-
Verve Therapeutics aims to tackle heart disease through gene editing
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
-
Oscar Health raises $165M as health insurance startup’s valuation surpasses $3B
The company has enrolled nearly 250,000 members across six states so far in 2018. Oscar has also projected sales of more than $1 billion in gross premium revenue.
-
Verily eyes overseas markets with $800M infusion from Singapore
The investment could pave the way for the kind of joint ventures and collaborations that Verily has embarked on with the likes of Sanofi, GSK, and others.